NPPA and myeloid sarcoma: Therefore, the development of more potent and specific KP inhibitors in conjunction with the function of already approved drugs involved in other signaling pathways, proposed here as repurposing drugs, may help to find new and promising approaches to discover protective mechanisms against myelin sheath damage and neuronal death to eventually provide effective therapies for the treatment of MS patients and improve their quality of life.